Europe Anticoagulant Reversal Drug Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Anticoagulant Reversal Drug Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Anticoagulant Reversal Drug Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Anticoagulant Reversal Drug Market Regional Analysis

6.2 Europe Anticoagulant Reversal Drug Market Revenue 2017-2027 (US$ Million)

6.3 Europe Anticoagulant Reversal Drug Market Forecast Analysis

7. Europe Anticoagulant Reversal Drug Market Analysis – by Product

7.1 Prothrombin Complex Concentrates

7.1.1 Overview
7.1.2 Prothrombin Complex Concentrates: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.2 Vitamin K

7.2.1 Overview
7.2.2 Vitamin K: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.3 Protamine

7.3.1 Overview
7.3.2 Protamine: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.4 Tranexamic Acid

7.4.1 Overview
7.4.2 Tranexamic Acid: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.5 Idarucizumab

7.5.1 Overview
7.5.2 Idarucizumab: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.6 AndeXXa

7.6.1 Overview
7.6.2 AndeXXa: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

8. Europe Anticoagulant Reversal Drug Market Analysis – by End User

8.1 Hospital Pharmacies

8.1.1 Overview
8.1.2 Hospital Pharmacies: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.2 Retail Pharmacies

8.2.1 Overview
8.2.2 Retail Pharmacies: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast, 2017-2027 (US$ Million)

9. Europe Anticoagulant Reversal Drug Market – Europe Analysis

9.1 Overview

9.2 Europe

9.2.1 Europe Anticoagulant Reversal Drug Market Breakdown, by Key Country, 2020 and 2027 (%)
9.2.1.1 Europe Anticoagulant Reversal Drug Market – Revenue and Forecast Analysis – by Country
9.2.1.1 UK: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast to 2027 (US$ Million)

9.2.1.1.1 UK: Europe Anticoagulant Reversal Drug Market Breakdown, by Product
9.2.1.1.2 UK: Europe Anticoagulant Reversal Drug Market Breakdown, by End User

9.2.1.2 Germany: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast to 2027 (US$ Million)

9.2.1.2.1 Germany: Europe Anticoagulant Reversal Drug Market Breakdown, by Product
9.2.1.2.2 Germany: Europe Anticoagulant Reversal Drug Market Breakdown, by End User

9.2.1.3 France: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast to 2027 (US$ Million)

9.2.1.3.1 France: Europe Anticoagulant Reversal Drug Market Breakdown, by Product
9.2.1.3.2 France: Europe Anticoagulant Reversal Drug Market Breakdown, by End User

9.2.1.4 Russia: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast to 2027 (US$ Million)

9.2.1.4.1 Russia: Europe Anticoagulant Reversal Drug Market Breakdown, by Product
9.2.1.4.2 Russia: Europe Anticoagulant Reversal Drug Market Breakdown, by End User

9.2.1.5 Italy: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast to 2027 (US$ Million)

9.2.1.5.1 Italy: Europe Anticoagulant Reversal Drug Market Breakdown, by Product
9.2.1.5.2 Italy: Europe Anticoagulant Reversal Drug Market Breakdown, by End User

9.2.1.6 Rest of Europe: Europe Anticoagulant Reversal Drug Market – Revenue and Forecast to 2027 (US$ Million)

9.2.1.6.1 Rest of Europe: Europe Anticoagulant Reversal Drug Market Breakdown, by Product
9.2.1.6.2 Rest of Europe: Europe Anticoagulant Reversal Drug Market Breakdown, by End User

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.3 Partnerships and Collaborations

11.4 Other Developments

12. Company Profiles

12.1 Boehringer Ingelheim International GmbH

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 Pfizer Inc

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 Octapharma AG

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 AMAG PHARMACEUTICALS, INC.

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Fresenius Kabi AG

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

12.7 CSL Limited

12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments

12.8 Grifols, S.A.

12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

Europe Anticoagulant Reversal Drug Market

Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa); End User (Hospital Pharmacies, Retail Pharmacies, and Others)